Nucana Plc (NCNA)
NASDAQ:NCNA
Want to see NCNA full AI Analyst Report?
NCNA Stock Chart & Stats
$2.03
-$0.06(-4.88%)
At close: 4:00 PM EST
$2.03
-$0.06(-4.88%)
Day’s Range― - ―
52-Week Range$1.33 - $39.80
Previous CloseN/A
Volume88.96K
Average Volume (3M)174.33K
Market Cap
$8.62M
Enterprise Value-$10.33M
Total Cash (Recent Filing)$21.53M
Total Debt (Recent Filing)$680.03K
Price to Earnings (P/E)―
Beta1.50
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.06
Shares Outstanding4,161,971
10 Day Avg. Volume84,221
30 Day Avg. Volume174,327
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.41
Price to Sales (P/S)0.00
P/FCF Ratio-1.42
Enterprise Value/Market Cap-1.20
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.46
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-8
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
ProTide Platform TechnologyNuCana’s ProTide platform is a structural competitive advantage: it chemically modifies nucleoside analogs to potentially improve tumor delivery and overcome resistance. That platform focus supports multiple pipeline assets and long-term optionality across solid tumors, underpinning durable R&D value.
Clinical Progress On NUC-7738 With Potential Registrational PathEncouraging Phase 2 signals and active pursuit of FDA guidance create a structural pathway to registration if confirmatory data are positive. A successful registrational strategy would convert R&D investment into a commercial product, materially altering the company's long-term revenue trajectory.
Low Financial Leverage And Extended Stated Cash RunwayVery low debt reduces default and interest risk, and management’s disclosure of a runway into 2029 (after 2025 financings) provides a durable cushion versus many peers. This lowers near-term refinancing urgency and supports continued clinical development absent adverse surprises.
Bears Say
Pre-revenue Status With Sustained LossesAs a clinical-stage biotech, NuCana has no product revenue and persistent net losses. Continued negative profitability means value depends entirely on future trial outcomes and financing; this structural lack of revenue leaves long-term viability tied to successful commercialization or recurring capital raises.
Ongoing Cash Burn And Reliance On Shareholder Approvals For FinancingThe company’s operating cash burn and declining cash balance force reliance on equity authorities and restructurings. Needing shareholder approval for fresh funding is a structural vulnerability: failure or dilution from future raises can constrain development or materially alter capital structure over time.
Binary Clinical And Regulatory Risk For PipelinePipeline value is binary: trial readouts and regulator decisions will determine commercial potential. Even with encouraging signals, negative or ambiguous Phase 2 data or adverse FDA feedback would materially impair the company’s long-term prospects given no diversifying revenue streams.
Nucana News
NCNA FAQ
What was Nucana Plc’s price range in the past 12 months?
Nucana Plc lowest stock price was $1.33 and its highest was $39.80 in the past 12 months.
What is Nucana Plc’s market cap?
Nucana Plc’s market cap is $8.62M.
When is Nucana Plc’s upcoming earnings report date?
Nucana Plc’s upcoming earnings report date is Aug 13, 2026 which is in 70 days.
How were Nucana Plc’s earnings last quarter?
Nucana Plc released its earnings results on May 14, 2026. The company reported $0 earnings per share for the quarter, the consensus estimate of N/A by $0.
Is Nucana Plc overvalued?
According to Wall Street analysts Nucana Plc’s price is currently Overvalued.
Does Nucana Plc pay dividends?
Nucana Plc does not currently pay dividends.
What is Nucana Plc’s EPS estimate?
Nucana Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nucana Plc have?
Nucana Plc has 4,161,971 shares outstanding.
What happened to Nucana Plc’s price movement after its last earnings report?
Nucana Plc reported an EPS of $0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went up 10.101%.
Which hedge fund is a major shareholder of Nucana Plc?
Currently, no hedge funds are holding shares in NCNA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nucana Plc
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors and in a Phase 1b/2 clinical trial for patients with advanced colorectal cancer; and NUC-7738, a nucleoside analog that is in Phase 1/2 clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
0.36% Other Institutional Investors
99.64% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---